Logo

Bergenbio Reports Results of Bemcentinib in P-II (ACCORD2) Study for the Treatment of COVID-19

Share this
Bergenbio Reports Results of Bemcentinib in P-II (ACCORD2) Study for the Treatment of COVID-19

Bergenbio Reports Results of Bemcentinib in P-II (ACCORD2) Study for the Treatment of COVID-19

Shots:

  • The P-II (ACCORD2) study evaluates bemcentinib + SoC vs SoC alone in hospitalized patients with COVID-19
  • The results showed that 90% experienced clinical response by day 29 (median 7.0 days) vs 69% (22 of 32 patients) to SoC alone (median 9.5 days), 98% received dexamethasone or an equivalent steroid in their SoC & 18% received immunomodulatory treatment with tocilizumab, antiviral remdesivir was used in 53% randomized to SoC alone & in 21% with bemcentinib
  • The 2EPs showed improvements including avoidance of deterioration by ≥1-point increase in WHO score & ventilator-free survival over 29 days, 97% vs 81% were alive @day 29, was well tolerated with no relevant safety signals

Ref: PRNewswire | Image: BerGen

Click here to­ read the full press release 

Neha

Neha Madan is a content writer at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions